Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
Peptide Analogs
A synthetic 16-residue cyclic peptide corresponding to the C-terminal domain of human growth hormone, characterized by NMR conformational analysis and bioanalytical structure studies.
Reviewed by Dr. James Whitfield, PharmD · Published · Last reviewed · For research use only.
Type
Synthetic peptide (cyclic, 16 residues)
Molecular formula
C78H123N23O23S2
Molecular weight
~1,815 g/mol
CAS number
221231-10-3
Amino acids
16
Sequence
YLRIVQCRSVEGSCGF
Modification
N-terminal tyrosine extension of the hGH 177–191 sequence; intramolecular Cys7–Cys14 disulfide bond forming a cyclic loop.
A disulfide-cyclized 16-residue peptide corresponding to the C-terminal domain of human growth hormone (residues 177–191 plus an N-terminal tyrosine). The N-terminal tyrosine extension and the intramolecular Cys7–Cys14 disulfide bond constrain the backbone into a cyclic loop; NMR conformational analysis of the solution structure identifies type I β-turns in this region. The cyclic loop is distinct from the N-terminal region of the full-length protein, and the tyrosine modification was introduced to improve stability relative to the unmodified C-terminal fragment.
Lyophilized
20 °C or colder, protected from light and moisture
stable for extended periods when kept frozen and sealed.
Avoid repeated freeze–thaw cycles; protect from light and moisture; the disulfide is oxidation-sensitive — avoid reducing agents. The N-terminal tyrosine modification was introduced to improve stability relative to the unmodified C-terminal fragment.
Reviews
Mendias CL, Awan TM. (2026). Sports Medicine
Kopchick JJ, et al. (2020). Nat Rev Endocrinol
Moré MI, Kenley D. (2014). Journal of Endocrinology and Metabolism
Reviews
Stier H, Vos E, Kenley D. (2013). Journal of Endocrinology and Metabolism
Liao HJ, et al. (2024). Cartilage
Vijayakumar A, et al. (2010). Growth Horm IGF Res
Primary research
Cox HD, et al. (2015). Drug Test Anal
Kwon DR, Park GY. (2015). Ann Clin Lab Sci
Vanhee C, et al. (2014). Drug Test Anal
Orlovius AK, et al. (2013). Drug Test Anal
Heffernan M, et al. (2001). Endocrinology
Heffernan MA, et al. (2001). Int J Obes
Heffernan MA, et al. (2000). Am J Physiol Endocrinol Metab
Ng FM, et al. (2000). Horm Res
Ng FM, et al. (2000). J Mol Endocrinol
Ogru E, et al. (2000). J Pept Res
Wijaya E, Ng FM. (1993). Biochem Mol Biol Int
Wu Z, Ng FM. (1993). Biochem Mol Biol Int
Ng FM, Bornstein J. (1978). American Journal of Physiology
Zhao L, Jiang H. (2023). Front Endocrinol
Høyer KL, et al. (2020). Physiol Rep
Also known as: hGH Fragment 176-191, Tyr-hGH 177-191
Research Use Only
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.
| Compound | Type | Molecular weight | CAS number |
|---|---|---|---|
| AOD-9604This page | Synthetic peptide (cyclic, 16 residues) | ~1,815 g/mol | 221231-10-3 |
| LUV RT | Synthetic peptide (acylated, 39 residues) | ~4,731 Da | 2381089-83-2 |
| LUV SM | Synthetic peptide (acylated, 31 residues) | ~4,114 g/mol | 910463-68-2 |
| LUV TRZ2 | Synthetic linear peptide (acylated, 39 residues) | ~4,814 g/mol | 2023788-19-2 |
| MOTS-c | Mitochondrial-derived peptide (16 residues) | ~2,175 g/mol | 1627580-64-6 |
Comparison of laboratory reference specifications only. For research use only; not a therapeutic comparison.
Quality & methods